INDOAMIN vs ROSSARI: Stock Comparison
ROSSARI BIOTECH is the larger company by market capitalisation. INDOAMIN shows a lower P/E, a higher ROE and a higher dividend yield, while ROSSARI BIOTECH shows faster revenue growth and lower leverage. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
INDOAMIN leads 7; ROSSARI leads 6 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | INDOAMIN | ROSSARI |
|---|---|---|
| Sector | Chemicals | Chemicals |
| Industry | Specialty Chemicals | Specialty Chemicals |
Price
| Metric | INDOAMIN | ROSSARI |
|---|---|---|
| Live Price | ₹137.95 | ₹446.15 |
| Day Change | -1.75% | -0.75% |
| Volume | 1.39 L | 36,449 |
| 52-Week High | ₹149 | ₹690.3 |
| 52-Week Low | ₹81.9 | ₹375 |
| Distance from 52W High | -7.42% | -35.37% |
Valuation
| Metric | INDOAMIN | ROSSARI |
|---|---|---|
| Market Cap | ₹928 Cr | ₹2,491 Cr |
| P/E Ratio | 11.47x | 16.53x |
| P/B Ratio | 2.37x | 1.87x |
| EPS | ₹4.22 | ₹6.34 |
| Book Value | ₹54.25 | ₹240.71 |
| Dividend Yield | 0.39% | 0.11% |
Growth
| Metric | INDOAMIN | ROSSARI |
|---|---|---|
| Revenue Growth (TTM YoY) | 11.3% | 18.2% |
| EPS Growth (TTM YoY) | 76% | 33.5% |
| Qtr Sales Growth | -1.96% | 44.56% |
| Qtr Profit Growth | -0.48% | 2.42% |
Profitability & Leverage
| Metric | INDOAMIN | ROSSARI |
|---|---|---|
| ROE | 20.14% | 11.19% |
| ROCE | 13.9% | 10.1% |
| Net Margin | 6.84% | 6.14% |
| Operating Margin | 11.2% | 9.56% |
| Debt to Equity | 0.79x | 0.31x |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | INDOAMIN | ROSSARI |
|---|---|---|
| Promoter Holding | 58.42% | 63.63%▼ 0.01 pp |
| FII Holding | 0.08%▲ 0.06 pp | 2.02%▼ 0.16 pp |
| DII Holding | 0% | 14.64%▼ 3.56 pp |
| Public Holding | 41.5%▼ 0.06 pp | 15.2%▲ 3.74 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: INDOAMIN and ROSSARI BIOTECH.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.